- $3.59m
- $2.91m
- $2.52m
- 23
- 39
- 16
- 14
Annual balance sheet for Onconetix, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | PROSPECTUS/A | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Short Term Investments | 4.31 | 1.93 | 25.8 | 4.55 | 0.646 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 0.01 | 0.153 | 0.036 | 0.15 | 0.096 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 4.6 | 3.07 | 26.3 | 5.84 | 0.95 |
| Net Property, Plant And Equipment | 0.016 | 0.011 | 0.014 | 0.209 | 0.182 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Other Long Term Assets | |||||
| Total Assets | 4.81 | 3.08 | 26.3 | 87.5 | 28.2 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 0.069 | 1.64 | 3.92 | 17.2 | 18.3 |
| Long Term Debt | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 0.078 | 1.64 | 3.92 | 28.9 | 18.6 |
| Redeemable Preferred Stock | |||||
| Non Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Treasury Stock | |||||
| Other Equity | |||||
| Total Equity | 4.73 | 1.45 | 22.4 | 58.6 | 9.61 |
| Total Liabilities & Shareholders' Equity | 4.81 | 3.08 | 26.3 | 87.5 | 28.2 |
| Total Common Shares Outstanding | |||||
| Total Preferred Shares Outstanding |